An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
NANO-X IMAGING LTD Files 2021 Annual Report on Form 20-F
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
NANO-X IMAGING LTD (Nasdaq: NNOX) has filed its annual report on Form 20-F for the fiscal year ended December 31, 2021, with the U.S. SEC on May 2, 2022. This report includes the company's audited consolidated financial statements, which can be accessed on the SEC's and Nanox's websites. Nanox aims to enhance diagnostic medicine accessibility and affordability through its proprietary imaging technology and solutions. Shareholders can request a hard copy of the annual report free of charge by contacting Investor Relations.
Positive
Filed annual report on Form 20-F, ensuring compliance with SEC regulations.
Focus on innovative medical imaging technology could enhance market position.
Negative
Lack of detailed financial performance metrics in the PR.
NEVE ILAN, Israel--(BUSINESS WIRE)--
NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the U.S. Securities and Exchange Commission (“SEC”) on May 2, 2022. The annual report on Form 20-F, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at www.sec.gov and on the Company’s website at www.nanox.vision under “Financials” in the Investors section.
The Company will provide a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to Investor Relations, at IR@nanox.vision.
About Nanox
Nanox (NASDAQ: NNOX) is focused on applying its proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable across the globe. The vision of Nanox is to increase the early detection of medical conditions that are discoverable by medical image technologies based on X-rays, which we believe is key to increasing early prevention and treatment, improving health outcomes, and, ultimately, saving lives. We are developing a holistic imaging solution, which includes the Nanox System, comprised of the Nanox.ARC using our novel MEMs X-ray source technology, and the Nanox.CLOUD, a companion cloud software, integrated with AI solutions and teleradiology services. Our vision is to increase early detection of medical conditions that are discoverable by X-ray by improving access to imaging, reducing imaging costs, and enhancing imaging efficiency, which we believe is key to increasing early prevention treatment, improving health outcomes and ultimately saving lives. For more information, please visit www.nanox.vision.
